<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02027389</url>
  </required_header>
  <id_info>
    <org_study_id>13-008045</org_study_id>
    <nct_id>NCT02027389</nct_id>
  </id_info>
  <brief_title>Impact of Rapid Detection of MRSA</brief_title>
  <official_title>Clinical and Economic Impact of a Rapid Test for Detection of Methicillin-resistant Staphylococcus Aureus (MRSA) From Sterile Sites (the Alere&amp;#8482; PBP2a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the impact of the Alere&amp;#8482; PBP2a test combined
      with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in
      hospitalized patients with sterile site S. aureus infection.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    personnel change, unable to continue study
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time (hours) to optimal antimicrobial therapy for patients with MSSA and MRSA infections in the pre-intervention and post-intervention periods</measure>
    <time_frame>within first 7 days of culture result</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time (in hours) to identification of MRSA.</measure>
    <time_frame>within first 3 days of culture result</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancomycin days of therapy following S. aureus culture result</measure>
    <time_frame>during the 2 weeks following culture result</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients with MSSA infection who are switched from an MRSA-active drug to an MSSA-active drug .</measure>
    <time_frame>within 48 hours of Gram-stain result</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of bacteremia in patients with MSSA or MRSA bloodstream infections</measure>
    <time_frame>within first 30 days of culture result</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to contact isolation in patients with MRSA infections</measure>
    <time_frame>within first 7 days of culture result</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>from time of culture result to hospital discharge, an expected average duration of 4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total healthcare costs (broken down by bed, laboratory, and pharmacy costs).</measure>
    <time_frame>from time of culture result to time of hospital discharge, an expected average duration of 4 weeks</time_frame>
    <description>participants will be followed for the duration of hospital stay following positive culture result, an expected average of 4 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients where a electronic (P-care) rule flagged for discordant therapy for the PBP2a result</measure>
    <time_frame>within first 3 days after culture result</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients where the pharmacist contacted the service to modify therapy</measure>
    <time_frame>wihtin first 7 days after culture result</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Staphylococcus Aureus Infections</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <description>Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus
        cultures between Sept 15, 2012 - Dec 31, 2012 (control) and Sept 15, 2013 - Dec 31, 2013
        (intervention)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S.
             aureus cultures (both control and intervention periods)

          2. Above, with rapid PBP2a testing (intervention period only).

        Exclusion criteria:

          1. Patients with polymicrobial cultures (i.e., growth of S. aureus plus other organisms
             in the culture).

          2. Patients who have not provided MN authorization to use their medical records for
             research.

          3. Patients who have had the FilmArray Blood culture identification diagnostic test
             performed on an index S. aureus blood culture.

          4. Patients who have had a sterile source S. aureus culture within the prior 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ritu Banerjee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2013</study_first_submitted>
  <study_first_submitted_qc>January 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2014</study_first_posted>
  <last_update_submitted>February 11, 2018</last_update_submitted>
  <last_update_submitted_qc>February 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ritu Banerjee, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>MSSA, MRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

